WO2008033395A3 - Melanocortin and transferrin fusion proteins - Google Patents

Melanocortin and transferrin fusion proteins Download PDF

Info

Publication number
WO2008033395A3
WO2008033395A3 PCT/US2007/019809 US2007019809W WO2008033395A3 WO 2008033395 A3 WO2008033395 A3 WO 2008033395A3 US 2007019809 W US2007019809 W US 2007019809W WO 2008033395 A3 WO2008033395 A3 WO 2008033395A3
Authority
WO
WIPO (PCT)
Prior art keywords
melanocortin
transferrin
moiety
fusion proteins
transferrin fusion
Prior art date
Application number
PCT/US2007/019809
Other languages
French (fr)
Other versions
WO2008033395A2 (en
Inventor
Homayoun Sadeghi
Christopher Philip Prior
Original Assignee
Biorexis Pharmaceutical Corp
Homayoun Sadeghi
Christopher Philip Prior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorexis Pharmaceutical Corp, Homayoun Sadeghi, Christopher Philip Prior filed Critical Biorexis Pharmaceutical Corp
Publication of WO2008033395A2 publication Critical patent/WO2008033395A2/en
Publication of WO2008033395A3 publication Critical patent/WO2008033395A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70582—CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention discloses fusion proteins comprising a transferrin moiety and a melanocortin or melanocortin receptor agonist moiety. In one embodiment of the invention, the transferrin moiety is modified to exhibit reduced or no glycosylation. In another embodiment, the transferrin moiety is modified to exhibit reduced or no binding to a transferrin receptor. The fusion protein of the invention can optionally comprise a linker peptide and/or a second therapeutic peptide such as GLP-1 or exendin-4. Also disclosed are methods of treating or preventing a disease or condition in a subject by administering a fusion protein of the invention.
PCT/US2007/019809 2006-09-14 2007-09-11 Melanocortin and transferrin fusion proteins WO2008033395A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84434806P 2006-09-14 2006-09-14
US60/844,348 2006-09-14

Publications (2)

Publication Number Publication Date
WO2008033395A2 WO2008033395A2 (en) 2008-03-20
WO2008033395A3 true WO2008033395A3 (en) 2008-05-15

Family

ID=39125184

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/019809 WO2008033395A2 (en) 2006-09-14 2007-09-11 Melanocortin and transferrin fusion proteins

Country Status (1)

Country Link
WO (1) WO2008033395A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009216681A1 (en) * 2008-02-22 2009-08-27 Clinuvel Pharmaceuticals Limited Method for treatment of photosensitivity and phototoxicity
WO2009147180A2 (en) * 2008-06-05 2009-12-10 Basf Se Microbicidal peptides of trichoderma reesei
WO2011046983A2 (en) 2009-10-12 2011-04-21 Smith Holdings, Llc Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
KR102188544B1 (en) 2010-11-30 2020-12-08 제넨테크, 인크. Low affinity blood brain barrier receptor antibodies and uses therefor
EP2968475A2 (en) 2013-03-14 2016-01-20 Questcor Pharmaceuticals, Inc. Acth for treatment of acute respiratory distress syndrome
WO2015162486A1 (en) * 2014-04-22 2015-10-29 Txp Pharma Gmbh Linear gamma msh with c- and / or n-terminal extensions of lysine and / or glutamic acid residues
WO2016069889A1 (en) * 2014-10-31 2016-05-06 Resolve Therapeutics, Llc Therapeutic nuclease-transferrin fusions and methods
CA3004933A1 (en) 2015-11-09 2017-05-18 Trustees Of Tufts College Bam8-22 peptide compounds and methods for treating pain
EP3526242A1 (en) 2016-10-12 2019-08-21 University of Copenhagen Peptide dual agonists of gipr and glp2r
CN107573414B (en) * 2017-08-14 2020-08-07 李翀 Human bladder cancer marker AG-CD71, antibody ABC71 and application thereof
ES2929416T3 (en) 2018-06-21 2022-11-29 Novo Nordisk As New compounds for the treatment of obesity
TW202345798A (en) * 2022-03-28 2023-12-01 南韓商Ｌｇ化學股份有限公司 Combination therapy for preventing or treating obesity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004020588A2 (en) * 2002-08-30 2004-03-11 Biorexis Pharmaceutical Corporation Transferrin fusion protein libraries
WO2004019872A2 (en) * 2002-08-30 2004-03-11 Biorexis Pharmaceutical Corporation Oral delivery of modified transferrin fusion proteins
WO2006017688A2 (en) * 2004-08-03 2006-02-16 Biorexis Pharmaceutical Corporation Combination therapy using transferrin fusion proteins comprising glp-1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004020588A2 (en) * 2002-08-30 2004-03-11 Biorexis Pharmaceutical Corporation Transferrin fusion protein libraries
WO2004019872A2 (en) * 2002-08-30 2004-03-11 Biorexis Pharmaceutical Corporation Oral delivery of modified transferrin fusion proteins
WO2006017688A2 (en) * 2004-08-03 2006-02-16 Biorexis Pharmaceutical Corporation Combination therapy using transferrin fusion proteins comprising glp-1

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE Geneseq [online] 27 January 2005 (2005-01-27), "Human transferrin protein.", XP002471765, retrieved from EBI accession no. GSP:ADU17611 Database accession no. ADU17611 *
MATSUBARA MUNEAKI ET AL: "Glucagon-like-peptide-1 fused to transferrin: A novel approach to myocardial reperfusion injury", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 49, no. 9, Suppl. A, March 2007 (2007-03-01), & 56TH ANNUAL SCIENTIFIC SESSION OF THE AMERICAN-COLLEGE-OF-CARDIOLOGY; NEW ORLEANS, LA, USA; MARCH 24 -27, 2007, pages 236A, XP009096973, ISSN: 0735-1097 *
MUNEAKI MATSUBARA, EARL ALBONE, JOSEPH H. GORMAN AND ROBERT C. GORMAN: "?-Melanocyte Stimulating Hormone Fused to Transferrin: A Novel Adjunct to Reperfusion Therapy for Acute MI", CARDIOVASCULAR PHYSIOLOGY, 1 August 2007 (2007-08-01), pages S92, XP002471736 *
RAFFIN-SANSON M L ET AL: "Proopiomelanocortin, a polypeptide precursor with multiple functions: From physiology to pathological conditions.", EUROPEAN JOURNAL OF ENDOCRINOLOGY, vol. 149, no. 2, August 2003 (2003-08-01), pages 79 - 90, XP002471746, ISSN: 0804-4643 *

Also Published As

Publication number Publication date
WO2008033395A2 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
WO2008033395A3 (en) Melanocortin and transferrin fusion proteins
WO2006024275A3 (en) Glp-1 and exendin related invention
WO2008036341A3 (en) Compositions and methods relating to glucagon receptor antibodies
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
GEP20146112B (en) Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and usage thereof
WO2008143954A3 (en) Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
WO2009133137A3 (en) Pegylated recombinant human growth hormone compounds
WO2008066752A8 (en) Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
WO2007028394A3 (en) Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
RU2014122609A (en) ANTIBODY MODIFIED CONSTANT AREA
WO2006096515A3 (en) Modified transferrin fusion proteins
WO2007130455A3 (en) Compositions and methods for treatment of non-hodgkins lymphoma
WO2007070671A3 (en) Therapeutic methods for inhibiting tumor growth with dll4 antagonists
MX2010002716A (en) Neuroendocrine factors for treatment of degenerative diseases.
WO2006041641A3 (en) Therapeutic agents with decreased toxicity
WO2006087637A3 (en) Anti her2/neu antibody
MX2009007290A (en) Glucagon-like protein-1 receptor (glp-1r) agonist compounds.
MX2009002999A (en) Protease resistant insulin analogues.
WO2006017688A3 (en) Combination therapy using transferrin fusion proteins comprising glp-1
WO2009147248A3 (en) Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
WO2007064727A3 (en) Penetrabodies: receptor-mediated targeted delivery of functionally-active human antibody fragments into cytosol for the treatment of chronic infections and diseases
WO2007091250A3 (en) Enzyme replacement therapy for treating lysosomal storage diseases
EP1945240A4 (en) Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
WO2006023359A3 (en) Selective vpac2 receptor peptide agonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07838084

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07838084

Country of ref document: EP

Kind code of ref document: A2